2024
DOI: 10.7759/cureus.60004
|View full text |Cite
|
Sign up to set email alerts
|

Rituximab Therapy for Double Seronegative Neuromyelitis Optica Spectrum Disease

Jose Carlos D Saballegue,
Ma. Luisa Gwenn P Tiongson

Abstract: Neuromyelitis optica spectrum disorder (NMOSD) is a rare central nervous system disease presenting as optic neuritis, myelitis, and brainstem syndromes. It may be aquaporin-4 seropositive, anti-myelin oligodendrocyte glycoprotein (MOG) antibody seropositive, or double seronegative. Double-seronegative NMOSD can pose a diagnostic and therapeutic challenge. Treatment typically aims to decrease the incidence of relapse, for which high-dose intravenous methylprednisolone is the first-line agent. Non-steroid treatm… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 9 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?